Project Details
| Status | Active |
|---|---|
| Effective start/end date | 05/9/23 → 12/31/26 |
Funding
- Provention Bio Incorporated: $90,257.87
Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants With at Least Two Autoantibodies and Dysglycemia)
- Quattrin, Teresa (PI)
Project: Research